Recombinant Anti-Tau (phospho S214) antibody [EPR1884(2)] (ab170892)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR1884(2)] to Tau (phospho S214)
- Suitable for: Dot blot, IHC-P, WB
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Tau (phospho S214) antibody [EPR1884(2)]
See all Tau primary antibodies -
Description
Rabbit monoclonal [EPR1884(2)] to Tau (phospho S214) -
Host species
Rabbit -
Specificity
The specificity of this antibody refers to P10636-8.
-
Tested applications
Suitable for: Dot blot, IHC-P, WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IP -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB:SH-SY5Y and C57 mouse cerebral cortex cell lysates. IHC: Human brain, normal spleen, normal kidney, cervical carcinoma and glioma tissues; Mouse brain tissue. Human AD cerebral cortex. Dot Blot:Tau (phospho S214) phospho peptide and Tau non-phospho peptide.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Dissociation constant (KD)
KD = 6.47 x 10 -11 M Learn more about KD -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR1884(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab170892 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot |
1/1000.
|
|
IHC-P |
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
|
WB |
1/1000 - 1/10000. Predicted molecular weight: 78 kDa.
|
Notes |
---|
Dot blot
1/1000. |
IHC-P
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
WB
1/1000 - 1/10000. Predicted molecular weight: 78 kDa. |
Target
-
Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. -
Tissue specificity
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system. -
Involvement in disease
Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. -
Sequence similarities
Contains 4 Tau/MAP repeats. -
Developmental stage
Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain. -
Domain
The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats. -
Post-translational
modificationsPhosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD. -
Cellular localization
Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components. - Information by UniProt
-
Database links
- Entrez Gene: 4137 Human
- Entrez Gene: 17762 Mouse
- Entrez Gene: 29477 Rat
- Omim: 157140 Human
- SwissProt: P10636 Human
- SwissProt: P10637 Mouse
- SwissProt: P19332 Rat
- Unigene: 101174 Human
see all -
Form
There are 9 isoforms produced by alternative splicing. -
Alternative names
- AI413597 antibody
- AW045860 antibody
- DDPAC antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human AD cerebral cortex tissue labelling Tau with ab170892 at 1/100 dilution. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody. Counterstained with hematoxylin.
Positive staining on human AD cerebral cortex without alkaline phosphatase treatment (image A). No signal was detected when tissues were treated with alkaline phosphatase (image B).
The section was incubated with ab170892 for 30 mins at room temperature. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument.
-
All lanes : Anti-Tau (phospho S214) antibody [EPR1884(2)] (ab170892) at 1/1000 dilution
Lane 1 : C57 mouse cerebral cortex whole cell lysates.
Lane 2 : C57 mouse cerebral cortex whole cell lysates. The membrane was incubated with phosphatase.
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 78 kDa
Observed band size: 50-70 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsBlocking/Diluting buffer and concentration: 5% NFDM/TBST
-
Immunohistochemical analysis of paraffin-embedded Human glioma tissue labeling Tau (phospho S214) with ab170892 at 1/100 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
ab170892 showing +ve staining in Mouse brain tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
All lanes : Anti-Tau (phospho S214) antibody [EPR1884(2)] (ab170892) at 1/1000 dilution
Lane 1 : SH-SY5Y cell lysates untreated
Lane 2 : SH-SY5Y cell lysates treated with Okadic acid + Calyculin A.
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 78 kDa -
Dot blot analysis of Tau (phospho S214) phospho peptide (Lane 1) and Tau non-phospho peptide (Lane 2) labeling Tau (phospho S214) with ab170892 at a dilution of 1/1000. ab97051 (Peroxidase conjugated goat anti-rabbit IgG) (H+L) at 1/100 000 was used as the secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
-
Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling Tau (phospho S214) with ab170892 at 1/100 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
ab170892 showing -ve staining in Human normal spleen tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
ab170892 showing -ve staining in Human normal kidney tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
ab170892 showing -ve staining in Human cervical carcinoma tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab170892 has been referenced in 10 publications.
- Quint WH et al. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. J Alzheimers Dis 80:813-829 (2021). PubMed: 33579845
- Jin M et al. Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. Commun Biol 4:961 (2021). PubMed: 34385591
- van der Hoven J et al. Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice. Sci Rep 10:13845 (2020). PubMed: 32796905
- Shim KH et al. Small-molecule drug screening identifies drug Ro 31-8220 that reduces toxic phosphorylated tau in Drosophila melanogaster. Neurobiol Dis 130:104519 (2019). PubMed: 31233882
- Stevens CH et al. Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. J Neuropathol Exp Neurol 78:605-614 (2019). PubMed: 31131395
- Hassaan PS et al. Cortical tau burden and behavioural dysfunctions in mice exposed to monosodium glutamate in early life. PLoS One 14:e0220720 (2019). PubMed: 31412065
- Yao X et al. Loss of miR-369 Promotes Tau Phosphorylation by Targeting the Fyn and Serine/Threonine-Protein Kinase 2 Signaling Pathways in Alzheimer's Disease Mice. Front Aging Neurosci 11:365 (2019). PubMed: 32082134
- Fujita K et al. Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. Nat Commun 9:433 (2018). PubMed: 29382817
- Wang T et al. Involvement of Insulin Signaling Disturbances in Bisphenol A-Induced Alzheimer's Disease-like Neurotoxicity. Sci Rep 7:7497 (2017). PubMed: 28790390
- Sun W et al. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment. Sci Rep 6:34784 (2016). WB . PubMed: 27708431